RankAlpha logo
Back to Rankings

TECH

Bio-TechneB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Q4 organic growth, improved adjusted margin, and stronger large-pharma, spatial-biology, and GMP-related trends support operational resilience. The $73 cash acquisition provides a visible near-term exit value.
Posture
Constructive
Lead driver
Value
What changed
4 setup hits (3d) with net bullish as of 2026-10-26.
What can break
Diagnostics and other businesses may remain volatile because of large-customer timing and unfavorable product mix.
Momentum
81
Value
59
Sentiment
51
Setup hits (3d)
4 · Net Bullish
AI TargetsBase $72.50 · Bull $73.00 · Bear $55.00Analysis 2026-08-14; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-14 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $73.00
Why
Momentum81 · Δ7d -0.1
Value59 · Δ7d -0.0
Sentiment51 · Δ7d -1.6
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • 4 setup hits (3d) with net bullish as of 2026-10-26.
  • • Value remains the lead driver in the composite, 7D delta -0.0.

Contradictions & invalidation

  • • Diagnostics and other businesses may remain volatile because of large-customer timing and unfavorable product mix.
  • • Full-year revenue was flat, and emerging-biotech demand remains uneven.
  • • The deal caps fundamental upside, full-year revenue was flat, adjusted EPS was slightly lower in Q4, and management previously noted that biotech funding had not translated into broad-based demand.

Catalyst clock

2026-08-12

Q4 FY2026 results showed modest organic growth and margin improvement

Lead driver: Value · See fundamentals
Momentum
81
8% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+8.3
Value
59
47% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.9
Sentiment
51
45% active weight
Current posture
7d trendSoftening
Δ7d
-1.6
Δ21d
-8.7
Why this grade

Composite grade B. Momentum 81.1 / Value 58.9 / Sentiment 51.0

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-14. Scenario method

B+
Bull case
25%
Probability
Target price
$73.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Most likely
B
Base case
60%
Probability
Target price
$72.50
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
B-
Bear case
15%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-08-14 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$11.4B
Beta
1.48
Shares Out
156.82M
P/E (TTM)
130.6
P/S (TTM)
8.07
P/FCF (TTM)
56.47
Rev YoY
+1.3%
EPS YoY
-404.4%
Gross Margin
+66.2%
Op Margin
+22.1%
Net Debt
$24.38M
Current Ratio
4.55
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data